WO1991007418A1 - Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen - Google Patents
Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen Download PDFInfo
- Publication number
- WO1991007418A1 WO1991007418A1 PCT/US1990/006620 US9006620W WO9107418A1 WO 1991007418 A1 WO1991007418 A1 WO 1991007418A1 US 9006620 W US9006620 W US 9006620W WO 9107418 A1 WO9107418 A1 WO 9107418A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- alo
- fragment
- chain
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
Definitions
- Plasmid pING1712 contains the following gene regulatory elements useful for expression in mammalian cells: 1) the IgH enhancer element, 2) the Abelson LTR promoter, 3) the SV40 16S splice site, and 4) a human K polyadenylation signal sequence. It also contains the entire human C ⁇ region (Liu, A.Y., et al. supra) and the GPJ gene which allows for ycophenolic acid resistance in transfected cells.
- the immune spleen cells and the mouse myeloma, P3U1 (Curr. Top. Microbiol. Immunol.. 81 . :1, 1979), were mixed in the ratio of about 2:1 (2.2 X 10 7 : 1.6 X 10 7 ) and a fusion reaction was carried out for 2 min. using 45% polyethylene glycol (average molecular weight: 4000) by a partial modification of the method of Kohler et al . (Immunological Methods. Academic Press, New York, p. 391, 1979). The treated cells were centrifuged, and the supernatant was discarded. The cells were then incubated for five minutes in HAT medium (see below) and inoculated into 96-well flat bottom microplates (0.1 ml per well) and cultured in 7.5% CO .
- Dulbecco's modified Eagle medium (DMEM) was obtained from Nissui Seiyaku Co.
- the polyadenylation/transcription termination region of the K expression vector was also modified.
- the first step was the Hindlll digestion and religation of plasmid pING2121a, which is identical to pING2108a (Liu, A.Y. et al.. supra) except that the L6 VL was used in its construction instead of the 2H7 VL, to form pING2121a-deltaH.
- the l.lkb Bglll to BamHI fragment of mouse genomic DNA distal to the polyadenylation site (Xu, M. et al.. J. Biol. Chem. 261: 3838 (1986) was isolated from pS107A (provided by Dr.
- the H chain enhancer was deleted from pING1711 by EcoRI digestion, T4 polymerase treatment, ligation to Aatll oligonucleotide linker, and cleavage and religation with Aatll to form the 7.7kb expression vector pING1714.
- the J-region mutagenesis primer 5'-GTTTTATTTCAAGCTTGGTCC-3' was used to insert a Hindlll site into the M13 subclone pTK2 to generate pTK4, and the oligonucleotide 5'-GAACTTTGGTCGACAGCAACGGG-3' was used to insert a Sail restriction site into pTK4 upstream of the initiation codon ATG to generate pTK5.
- the restriction fragment containing the AlO VL region bounded by Sail and Hindlll was then cloned into the expression vector pING1712 to generate the final chimeric AlO L chain expression vector, pING2252.
- the approxi ⁇ mately 340 bp fragment containing the Fd V-region was purified and ligated to pING1500 that was cut with Sstl, treated with T4 polymerase, and cut with Xhol, Figure 5E, along with the BstEII (partial digest) to Xhol restriction fragment containing the human Fd C region and 3 nucleotides following the termination codon from pF3D, Figure 5F, (the human C ⁇ l region in pF3D was previously generated by introducing a stop codon in hinge, Robinson, R.R. et al . , supra) .
- the resulting plasmid that contained a pelB::A10 Fd fusion was sequenced to determine that the proper in-frame fusion was formed. This plasmid was called pTK13.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43501289A | 1989-11-13 | 1989-11-13 | |
US435,012 | 1989-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991007418A1 true WO1991007418A1 (en) | 1991-05-30 |
Family
ID=23726623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006620 WO1991007418A1 (en) | 1989-11-13 | 1990-11-13 | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0457875A4 (ko) |
JP (1) | JPH03206886A (ko) |
KR (1) | KR910009284A (ko) |
AU (1) | AU634314B2 (ko) |
CA (1) | CA2044590A1 (ko) |
WO (1) | WO1991007418A1 (ko) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
WO1997037690A2 (en) * | 1996-04-10 | 1997-10-16 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
WO1998034645A1 (en) * | 1997-02-05 | 1998-08-13 | Angelini Ricerche S.P.A. Societa' Consortile | A composition for administration by the intranasal, sublingual or vaginal route |
US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
US7033594B2 (en) | 2000-03-31 | 2006-04-25 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
EP2060272A2 (en) | 2002-05-15 | 2009-05-20 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US7696324B2 (en) | 1998-11-30 | 2010-04-13 | Perlan Therapeutics, Inc. | Humanized antibodies |
EP2374480A2 (en) | 2005-08-19 | 2011-10-12 | Endocyte, Inc. | Mutli-drug ligand conjugates |
EP2382995A2 (en) | 2005-08-19 | 2011-11-02 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
EP2481427A1 (en) | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
EP2517729A2 (en) | 2003-01-27 | 2012-10-31 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US8394771B1 (en) | 2001-07-19 | 2013-03-12 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
US8907058B2 (en) | 2007-08-17 | 2014-12-09 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9090563B2 (en) | 2004-07-23 | 2015-07-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9505747B2 (en) | 2012-03-29 | 2016-11-29 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US9636413B2 (en) | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US9662402B2 (en) | 2012-10-16 | 2017-05-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9958456B2 (en) | 2011-10-07 | 2018-05-01 | Baxalta Incorporated | OxMIF as a diagnostic marker |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US10398791B2 (en) | 2013-10-18 | 2019-09-03 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10624972B2 (en) | 2015-03-13 | 2020-04-21 | Endocyte, Inc. | Conjugates for treating diseases |
US10898596B2 (en) | 2015-01-07 | 2021-01-26 | Endocyte, Inc. | Conjugates for imaging |
WO2022219569A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Folate receptor-targeted radiotherapeutic agents and their use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
GB8800078D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
IL89489A0 (en) * | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
-
1990
- 1990-11-13 AU AU66641/90A patent/AU634314B2/en not_active Ceased
- 1990-11-13 WO PCT/US1990/006620 patent/WO1991007418A1/en not_active Application Discontinuation
- 1990-11-13 JP JP2308453A patent/JPH03206886A/ja active Pending
- 1990-11-13 CA CA002044590A patent/CA2044590A1/en not_active Abandoned
- 1990-11-13 KR KR1019900018568A patent/KR910009284A/ko not_active Application Discontinuation
- 1990-11-13 EP EP19910900650 patent/EP0457875A4/en not_active Withdrawn
Non-Patent Citations (6)
Title |
---|
Nucleic Acids Research, Volume 12, No. 24, issued 1984, W. KRAMER, et al., "The Gapped Duplex DNA approach to oligonucleotide-directed mutation construction", pages 9441-9456. * |
Proceedings of The National Academy of Science, Volume 82, issued February 1985, A.N. HOUGHTON, et al., "Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma, pages 1242-1246. * |
Proceedings of the National Academy of Science, Volume 84, issued May 1987, A.Y. LIU, et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells", pages 3439-3443, see Abstract and pages 3439-40. * |
See also references of EP0457875A4 * |
The Journal of Biological Chemistry, Volume 261 No. 8, issued 15 March 1986, XU, et al., "Transcription Termination and Chromatin Structure of the Active Immunoglobulin k Gene Locus", pages 3838-3845. * |
The Journal of Immunology, Volume 139, No. 10 issued 15 November 1987, A.Y. LIU, et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody To CD20 With Potent Fc-Dependent Biologic Activity", pages 3521-3526. See Abstract. * |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517523B2 (en) | 1993-05-17 | 2009-04-14 | Cytokine Pharmasciences, Inc. | Anti-MIF antibodies |
US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
WO1997037690A2 (en) * | 1996-04-10 | 1997-10-16 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
WO1997037690A3 (en) * | 1996-04-10 | 1998-03-05 | Sangstat Medical Corp | Cytomodulating conjugates of members of specific binding pairs |
WO1998034645A1 (en) * | 1997-02-05 | 1998-08-13 | Angelini Ricerche S.P.A. Societa' Consortile | A composition for administration by the intranasal, sublingual or vaginal route |
US7696324B2 (en) | 1998-11-30 | 2010-04-13 | Perlan Therapeutics, Inc. | Humanized antibodies |
US8586712B2 (en) | 1998-11-30 | 2013-11-19 | Perlan Therapeutics, Inc. | Humanized antibodies |
US7033594B2 (en) | 2000-03-31 | 2006-04-25 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
US8105608B2 (en) | 2000-03-31 | 2012-01-31 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
US8394771B1 (en) | 2001-07-19 | 2013-03-12 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
EP2060272A2 (en) | 2002-05-15 | 2009-05-20 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US7910594B2 (en) | 2002-05-15 | 2011-03-22 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
EP2517729A2 (en) | 2003-01-27 | 2012-10-31 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
EP2529758A2 (en) | 2003-01-27 | 2012-12-05 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
EP2517730A2 (en) | 2003-01-27 | 2012-10-31 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US10647676B2 (en) | 2004-07-23 | 2020-05-12 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US9090563B2 (en) | 2004-07-23 | 2015-07-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US9550734B2 (en) | 2004-07-23 | 2017-01-24 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP2382995A2 (en) | 2005-08-19 | 2011-11-02 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
EP2374480A2 (en) | 2005-08-19 | 2011-10-12 | Endocyte, Inc. | Mutli-drug ligand conjugates |
US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
EP2481427A1 (en) | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
EP2489372A2 (en) | 2007-03-14 | 2012-08-22 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US9555139B2 (en) | 2007-03-14 | 2017-01-31 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US10738086B2 (en) | 2007-06-25 | 2020-08-11 | Endocyte Inc. | Conjugates containing hydrophilic spacer linkers |
US10500204B2 (en) | 2007-06-25 | 2019-12-10 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
EP3569251A1 (en) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US10646581B2 (en) | 2007-08-17 | 2020-05-12 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10517957B2 (en) | 2007-08-17 | 2019-12-31 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11083710B2 (en) | 2007-08-17 | 2021-08-10 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11318121B2 (en) | 2007-08-17 | 2022-05-03 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10828282B2 (en) | 2007-08-17 | 2020-11-10 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US8907058B2 (en) | 2007-08-17 | 2014-12-09 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10046054B2 (en) | 2007-08-17 | 2018-08-14 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9193763B2 (en) | 2007-08-17 | 2015-11-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11717514B2 (en) | 2007-08-17 | 2023-08-08 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10406240B2 (en) | 2007-08-17 | 2019-09-10 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11369590B2 (en) | 2007-08-17 | 2022-06-28 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10624970B2 (en) | 2007-08-17 | 2020-04-21 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10485878B2 (en) | 2007-08-17 | 2019-11-26 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10624971B2 (en) | 2007-08-17 | 2020-04-21 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10517956B2 (en) | 2007-08-17 | 2019-12-31 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US11298341B2 (en) | 2007-08-17 | 2022-04-12 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10624969B2 (en) | 2007-08-17 | 2020-04-21 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9745341B2 (en) | 2007-10-25 | 2017-08-29 | Endocyte, Inc. | Tubulysins and processes for preparing |
US11155800B2 (en) | 2010-02-25 | 2021-10-26 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10557128B2 (en) | 2010-02-25 | 2020-02-11 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US9958456B2 (en) | 2011-10-07 | 2018-05-01 | Baxalta Incorporated | OxMIF as a diagnostic marker |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US10765756B2 (en) | 2012-02-24 | 2020-09-08 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US11344623B2 (en) | 2012-02-24 | 2022-05-31 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US9505747B2 (en) | 2012-03-29 | 2016-11-29 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US9662402B2 (en) | 2012-10-16 | 2017-05-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
US9636413B2 (en) | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US10912840B2 (en) | 2012-11-15 | 2021-02-09 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US9782493B2 (en) | 2012-11-15 | 2017-10-10 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US10471160B2 (en) | 2013-10-18 | 2019-11-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US11045564B2 (en) | 2013-10-18 | 2021-06-29 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer |
US10398791B2 (en) | 2013-10-18 | 2019-09-03 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US11931430B2 (en) | 2013-10-18 | 2024-03-19 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer |
US11951190B2 (en) | 2013-10-18 | 2024-04-09 | Novartis Ag | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer |
US10898596B2 (en) | 2015-01-07 | 2021-01-26 | Endocyte, Inc. | Conjugates for imaging |
US10624972B2 (en) | 2015-03-13 | 2020-04-21 | Endocyte, Inc. | Conjugates for treating diseases |
WO2022219569A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Folate receptor-targeted radiotherapeutic agents and their use |
Also Published As
Publication number | Publication date |
---|---|
AU634314B2 (en) | 1993-02-18 |
KR910009284A (ko) | 1991-06-28 |
AU6664190A (en) | 1991-05-23 |
EP0457875A1 (en) | 1991-11-27 |
EP0457875A4 (en) | 1993-03-03 |
JPH03206886A (ja) | 1991-09-10 |
CA2044590A1 (en) | 1991-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU634314B2 (en) | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen | |
EP0364096B1 (en) | Gene expression elements and the production of chimeric mouse-human antibodies | |
US5576184A (en) | Production of chimeric mouse-human antibodies with specificity to human tumor antigens | |
EP0731167B1 (en) | Modular assembly of antibody genes, antibodies prepared thereby and use | |
US5500362A (en) | Chimeric antibody with specificity to human B cell surface antigen | |
EP0266663B1 (en) | Chimeric antibody with specificity to human tumor antigen | |
US5576195A (en) | Vectors with pectate lyase signal sequence | |
US5618920A (en) | Modular assembly of antibody genes, antibodies prepared thereby and use | |
US20050163708A1 (en) | Chimeric antibody with specificity to human B cell surface antigen | |
EP0404003A2 (en) | Chimeric mouse-human KM10 antibody with specificity to a human tumor cell antigen | |
US20050196400A1 (en) | Production of chimeric mouse-human antibodies with specificity to human tumor antigens | |
AU606653C (en) | Chimeric antibody with specificity to human B cell surface antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2044590 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991900650 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991900650 Country of ref document: EP |
|
WR | Later publication of a revised version of an international search report | ||
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991900650 Country of ref document: EP |